FDA announces new network to focus exclusively on patients

FDA announces new network to focus exclusively on patients
The U.S. Food and Drug Administration has announced the launch of a new interactive tool for educating patients, their advocates, and consumers about the processes involved in medication development.

(HealthDay)—The U.S. Food and Drug Administration has announced the launch of a new interactive tool for educating patients, their advocates, and consumers about the processes involved in medication development.

Since the early 1990s, the FDA has been working directly with patients and their advocates to help them understand about product development and regulation. This includes patient representatives who participate in FDA advisory meetings. Patient input will be more focused and valuable when they better understand how are studied, reviewed, assessed, and brought to market.

The interactive FDA Patient Network website educates patients, their advocates, and consumers about the development of prescription and over-the-counter medications. New channels of communication will be available, including live chats with senior agency officials. With the launch of this website and the increased ability for patients to understand the safety processes involved in drug development, it is hoped that the role of patients can be expanded to a wider audience in new and broader ways.

"I am excited because this new Patient Network website provides a for FDA to follow in making its inner workings transparent to the public," Margaret A. Hamburg, M.D., Commissioner of the FDA, said in a statement. "It ushers in a new era of access and input for patients and consumers that will evolve with the needs of both communities."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

FDA Web site explains agency operations to public

Jan 12, 2010

(AP) -- The Food and Drug Administration is launching a new Web site explaining its operations to consumers as part of a broader effort to rebrand itself as a more accessible agency.

FDA: Draft guidance issued on abuse-deterrent opioids

Jan 10, 2013

(HealthDay)—The U.S. Food and Drug Administration has issued a draft guidance document to assist the pharmaceutical industry in developing new formulations of opioid drugs with abuse-deterrent properties.

FDA weighs over-the-counter switch for key drugs

Mar 08, 2012

Some of the most widely used prescription drugs, including those to treat cholesterol and high blood pressure, could be available over the counter under a new proposal being weighed by government regulators.

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments